Clinical trials: HGSOC
High Grade Serous Ovarian Cancer (HGSOC)
68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study
The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan.
- Trial name
- FAST HOC (NCT05956093)
- Testing
- FAPI PET CT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
High Grade Ovarian Serous Adenocarcinoma, High Grade Serous Carcinoma
Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
Chemotherapy resistance is the greatest contributor to mortality in advanced cancers and severe challenges remain in finding effective treatment modalities to cancer patients with metastasized and relapsed disease.
- Trial name
- DECIDER (NCT04846933)
- Testing
- WGS and RNA sequencing, circulating tumor DNA (ctDNA), FDG PET/CT imaging
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Turku University Hospital
High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for…
- Conditions
- High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07432594
- Testing
- Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5)
- Volunteers
- 82 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
- Conditions
- High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT06476808
- Testing
- BMS-986463
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 240 people
- Sponsor
- Bristol-Myers Squibb
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a…
- Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
- Trial name
- NCT04092270
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 11 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian…
- Conditions
- Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC)
- Trial name
- MATAO (NCT04111978)
- Testing
- Letrozole 2.5mg
- Where
- 53 sites in Austria, Germany and 1 more
- Volunteers
- 540 people
- Sponsor
- Swiss GO Trial Group
Platinum-resistant Epithelial Ovarian Cancer
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.
- Trial name
- AVALON (NCT05243524)
- Testing
- Maveropepimut-S, Cyclophosphamide 50mg
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 16 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back.
- Conditions
- High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT02756130
- Testing
- Birinapant, Carboplatin, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovary Cancer
Mesenteric Infiltration in Ovarian Cancer
To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an…
- Trial name
- MIO (NCT06331130)
- Testing
- Computed Tomography
- Where
- Italy
- Volunteers
- 510 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Ovarian Cancer Stage IIIC, Fallopian Tube Cancer Stage IIIC
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
This is a monocenter, interventional, non-randomized study among women patients with an ovarian or tubal cancer who will receive a surgery or adjuvant chemotherapy treatment, or a neo-adjuvant chemotherapy then surgery +/…
- Conditions
- Ovarian Cancer Stage IIIC, Fallopian Tube Cancer Stage IIIC, Fallopian Tube Cancer Stage IV, Ovarian Cancer Stage IV
- Trial name
- TILsOV (NCT03922776)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Oscar Lambret
Advanced Solid Tumors
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT04293094
- Testing
- AMG 650
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 66 people
- Sponsor
- Volastra Therapeutics, Inc.
Ovarian Carcinoma
PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma
Single center, phase I/II randomized 2-arm study, evaluating two different vaccination regimens combined with low-dose cyclophosphamide in patients with advanced high grade serous ovarian carcinoma (HGSOC): Arm A patients will be…
- Trial name
- CHUV-OVACURE (NCT05714306)
- Testing
- PEP-DC1, OC-DC, PEP-DC2
- Sponsor
- Centre Hospitalier Universitaire Vaudois
HGSOC
Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings
To compare DHODH protein expression in HGSC tissues from patients undergoing Primary Debulking Surgery (PDS - Chemo-naive) versus Interval Debulking Surgery (IDS - Post-NACT).
- Trial name
- HGSOC (NCT07366242)
- Testing
- Immunohistochemical (IHC) assessment of DHODH expression, No interventions as it is observational study
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Heba Ahmed Mohamed
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Ovarian Cancer, Fallopian Tube Cancer
BEACON - ABC in Recurrent Platinum Resistant HGSOC
Epithelial ovarian cancer (EOC) is the ninth most common cause of cancer in Australian women, with an estimated 1500 new diagnoses in Australia in 2015, and remains the seventh most common cause of cancer death in Australian…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- BEACON (NCT03363867)
- Testing
- Atezolizumab, Bevacizumab, Cobimetinib
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Conditions
- Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
- Trial name
- NCT05005403
- Testing
- Azirkitug, Budigalimab, Bevacizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 694 people
- Sponsor
- AbbVie
Ovarian Neoplasms
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
The primary purpose is to assess the safety and tolerability of tilvestamab following IV administration of multiple doses to participants with HGSOC who have been treated with at least 1 complete course of platinum-based…
- Trial name
- NCT04893551
- Testing
- Tilvestamab
- Where
- 9 sites in Norway, Singapore and 2 more
- Volunteers
- 16 people
- Sponsor
- BerGenBio ASA